The Quantellect read.As of Nov 19, 2026, 4 active firms cover Cellebrite DI: 4 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $12.50 to $16.00, so the covering firms are broadly aligned. The average target of $14.63 sits 31% above the current $11.17. The rating mix has stayed broadly stable, with Buy-side ratings easing from 5 to 4 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.15 next quarter toward $0.67 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 active firms
Buy
Strong Buy00%
Buy4100%
Neutral00%
Sell00%
Strong Sell00%
Based on 4 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$14.63
+30.9% upside
Average target across 4 active firms as of Nov 19, 2026 vs $11.17 current
Highest Target$16.00
Average Target$14.63
Lowest Target$12.50
Detailed analyst forecasts for CLBT
Showing 1–4 of 4 named analysts shown · 4 active firms in the rating projection
As of Nov 19, 2026, 4 of 4 active firms rate CLBT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CLBT EPS & revenue forecast
EPS · NEXT QUARTER
$0.15
Range $0.12 – $0.17 · 6 analysts · +21% YoY
Next period, 6 analysts expect Cellebrite DI to earn $0.15 a share (range $0.12 – $0.17), versus $0.12 a year earlier. Full-year consensus is $0.58, growing to $0.67 the year after.
REVENUE · NEXT QUARTER
$145.6M
Range $142.0M – $151.0M · 6 analysts · +13% YoY
Revenue is expected to reach $145.6M (range $142.0M – $151.0M), +13.5% year-over-year. Full-year consensus is $555.5M, rising to $627.0M next year.
Top analysts covering Cellebrite DI
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CLBT.
#1
Mike Cikos
Needham · Rank #296
Buy
$12.50+11.9% to target
Overall win rate
45%
+ Follow
#2
Frank Takkinen
Lake Street · Rank #514
Buy
$15.00+34.3% to target
Overall win rate
27%
+ Follow
#3
Eric Martinuzzi
Lake Street · Rank #530
Buy
$15.00+34.3% to target
Overall win rate
23%
+ Follow
#4
Rudy Kessinger
DA Davidson
Buy
$15.00+34.3% to target
Coverage
—
+ Follow
#5
BE
Brian Essex
JP Morgan
Buy
$16.00+43.2% to target
Coverage
—
+ Follow
CLBT stock forecast FAQ
What is CLBT's average 12-month price target?+
The 4 active firms with a live target average $14.63 for Cellebrite DI over the next 12 months, ranging from a $16.00 high to a $12.50 low, as of Nov 19, 2026.
Is CLBT stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 4 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for CLBT?+
The Street-high target is $16.00 (JP Morgan), and the Street-low is $12.50 (Needham). The average of all 4 active-firm targets is $14.63.
How many active Wall Street firms cover CLBT?+
4 active firms have a recognized rating on Cellebrite DI as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CLBT?+
Among analysts who currently cover CLBT, Mike Cikos of Needham has the strongest overall Quantellect track record (Rank #296). Their current call is Buy with a $12.50 target.
What is Cellebrite DI's projected EPS for next quarter?+
The consensus estimate is $0.15 per share (range $0.12 – $0.17) across 6 analysts. Full-year EPS is projected at $0.58, rising to $0.67 the following year.
How much revenue is Cellebrite DI expected to report next quarter?+
Consensus revenue is $145.6M (range $142.0M – $151.0M). Full-year revenue is projected at $555.5M, growing to $627.0M next year.
Have analysts been upgrading or downgrading CLBT lately?+
As of Nov 19, 2026, 4 of 4 active firms rate CLBT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CLBT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.